Literature DB >> 10586956

Retinal pathology of canine X-linked progressive retinal atrophy, the locus homologue of RP3.

C J Zeiss1, G M Acland, G D Aguirre.   

Abstract

PURPOSE: To describe the course of photoreceptor disease in canine X-linked retinal degeneration.
METHODS: Retinas from 55 dogs (44 males, 8 carrier females, 3 homozygous females) were obtained by enucleation under general anesthesia. After fixation and dehydration, tissues were embedded in epoxy resin, sectioned at 1 microm for light microscopy and stained with azure II/methylene blue and a paraphenylenediamine counterstain. For electron microscopy, regions identified by light microscopy were selected and cut at 60 nm. Sections were stained with uranyl acetate-lead citrate. Electroretinography from an additional group of normal males, affected males, and carrier females was performed and the rod and cone responses evaluated.
RESULTS: The earliest lesion detectable by electron microscopy was vesiculation of rod discs, followed by disruption of outer segments and death of rods. Loss of cones and progressive atrophy of inner retinal layers followed. Lesions were most severe in the peripheral retina and advanced toward the optic disc with disease progression. Significant variation in disease severity was present in males despite the presence of the same disease allele in all affected dogs. Carrier females displayed generalized reduction in photoreceptor density as well as multifocal areas of complete rod loss. The electroretinogram (ERG) findings were compatible with the histopathologic abnormalities. Homozygous females had lesions similar to those seen in affected males.
CONCLUSIONS: X-linked retinal degeneration is characterized by initial degeneration of rod photoreceptors, followed by loss of cones and progressive atrophy of the inner retina. Carrier females display a phenotype consistent with random X-chromosome inactivation. Variation in genetic background may alter expression of the disease allele in affected animals, thus accounting for variation in phenotypic expression of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10586956

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

1.  Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa.

Authors:  William A Beltran; Artur V Cideciyan; Alfred S Lewin; Simone Iwabe; Hemant Khanna; Alexander Sumaroka; Vince A Chiodo; Diego S Fajardo; Alejandro J Román; Wen-Tao Deng; Malgorzata Swider; Tomas S Alemán; Sanford L Boye; Sem Genini; Anand Swaroop; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies.

Authors:  Keiko Miyadera; Gregory M Acland; Gustavo D Aguirre
Journal:  Mamm Genome       Date:  2011-11-08       Impact factor: 2.957

Review 3.  Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms.

Authors:  Paulo A Ferreira
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

Review 4.  Gene augmentation for X-linked retinitis pigmentosa caused by mutations in RPGR.

Authors:  William A Beltran; Artur V Cideciyan; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

5.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

6.  Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa.

Authors:  Valérie L Dufour; Artur V Cideciyan; Guo-Jie Ye; Chunjuan Song; Adrian Timmers; Perry L Habecker; Wei Pan; Nicole M Weinstein; Malgorzata Swider; Amy C Durham; Gui-Shuang Ying; Paulette M Robinson; Samuel G Jacobson; David R Knop; Jeffrey D Chulay; Mark S Shearman; Gustavo D Aguirre; William A Beltran
Journal:  Hum Gene Ther       Date:  2020-02-06       Impact factor: 5.695

7.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

8.  Inner retinal abnormalities in X-linked retinitis pigmentosa with RPGR mutations.

Authors:  Tomas S Aleman; Artur V Cideciyan; Alexander Sumaroka; Sharon B Schwartz; Alejandro J Roman; Elizabeth A M Windsor; Janet D Steinberg; Kari Branham; Mohammad Othman; Anand Swaroop; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

Review 9.  The use of canine models of inherited retinal degeneration to test novel therapeutic approaches.

Authors:  William A Beltran
Journal:  Vet Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.644

10.  Analysis of six candidate genes as potential modifiers of disease expression in canine XLPRA1, a model for human X-linked retinitis pigmentosa 3.

Authors:  Richard Guyon; Susan E Pearce-Kelling; Caroline J Zeiss; Gregory M Acland; Gustavo D Aguirre
Journal:  Mol Vis       Date:  2007-07-11       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.